EUVIMEDEUVIMED entdecken
Crossref

Advancements in NMDA Receptor-Targeted Antidepressants: From d -Cycloserine Discovery to Preclinical Efficacy of Lu AF90103

Erhad Ascic iD, Mauro Marigo, Laurent David, Kjartan Frisch Herrik, Morten Grupe, Charlotte Hougaard, Arne Mørk, Christopher R Jones, Lassina Badolo, Kristen Frederiksen, Harrie C M Boonen iD, Henrik Sindal Jensen und 1 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Erhad Ascic und 12 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, Valby, DK-2500 Copenhagen, Denmark. Hauptthemen laut MEDLINE: Receptors, N-Methyl-D-Aspartate, Cycloserine, Antidepressive Agents, Rats, Sprague-Dawley. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery of d-cycloserine (DCS), a partial agonist of the NMDA receptor that exhibits antidepressant effects without the psychotomimetic effects of ketamine, has fueled interest in new NMDA-targeting antidepressants. Our objective was to identify potent partial agonists mirroring DCS, particularly tailored for the GluN2B subtype of the NMDA receptor. Through a structure-based drug design approach, we discovered compound 42d. This compound acts as a partial agonist of the GluN1/GluN2B complex, exhibiting 24% efficacy, and has an EC50 value of 78 nM. Subsequent investigations led us to 42e (Lu AF90103), a methyl ester prodrug of 42d capable of penetrating the blood-brain barrier, as confirmed by rat microdialysis studies. In different rat in vivo models relevant to neuropsychiatric diseases, administering 42e led to 42d demonstrating both acute effects, observed in a seizure model and EEG, and lasting effects in the stress-sensitive hippocampal pathway and an antidepressant-sensitive model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, N-Methyl-D-AspartateCycloserineAntidepressive AgentsRats, Sprague-DawleyAnimalsRatsMaleDrug DiscoveryHumansStructure-Activity RelationshipBlood-Brain BarrierSeizuresProdrugs

Substanzen

Receptors, N-Methyl-D-AspartateCycloserineAntidepressive AgentsProdrugs

Autor:innen und Institutionen

  • Neuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, Valby, DK-2500 Copenhagen, Denmark.

ORCID-Profile: Erhad Ascic, Harrie C M Boonen

Zitieren

APA

Ascic, E., Marigo, M., David, L., Frisch Herrik, K., Grupe, M., Hougaard, C., Mørk, A., Jones, C. R., Badolo, L., Frederiksen, K., Boonen, H. C. M., Jensen, H. S., & Kilburn, J. P. (2024). Advancements in NMDA Receptor-Targeted Antidepressants: From d -Cycloserine Discovery to Preclinical Efficacy of Lu AF90103. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01477

Vancouver

Ascic E, Marigo M, David L, Frisch Herrik K, Grupe M, Hougaard C, et al. Advancements in NMDA Receptor-Targeted Antidepressants: From d -Cycloserine Discovery to Preclinical Efficacy of Lu AF90103. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01477

BibTeX
@article{Ascic2024,
  author = {Ascic, Erhad and Marigo, Mauro and David, Laurent and Frisch Herrik, Kjartan and Grupe, Morten and Hougaard, Charlotte and Mørk, Arne and Jones, Christopher R and Badolo, Lassina and Frederiksen, Kristen and Boonen, Harrie C M and Jensen, Henrik Sindal and Kilburn, John Paul},
  title = {Advancements in NMDA Receptor-Targeted Antidepressants: From d -Cycloserine Discovery to Preclinical Efficacy of Lu AF90103},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01477}
}
Kostenlos starten →